X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Strides Arcolab with Sun Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES SHASUN LTD vs SUN PHARMA - Comparison Results

STRIDES SHASUN LTD    Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES SHASUN LTD SUN PHARMA STRIDES SHASUN LTD/
SUN PHARMA
 
P/E (TTM) x 14.0 15.3 91.5% View Chart
P/BV x 1.9 3.6 52.6% View Chart
Dividend Yield % 0.5 0.2 258.2%  

Financials

 STRIDES SHASUN LTD   SUN PHARMA
EQUITY SHARE DATA
    STRIDES SHASUN LTD
Mar-16
SUN PHARMA
Mar-16
STRIDES SHASUN LTD/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs1,4131,201 117.6%   
Low Rs848706 120.0%   
Sales per share (Unadj.) Rs353.3117.5 300.7%  
Earnings per share (Unadj.) Rs23.419.6 119.3%  
Cash flow per share (Unadj.) Rs41.023.8 172.2%  
Dividends per share (Unadj.) Rs5.001.00 500.0%  
Dividend yield (eoy) %0.40.1 421.8%  
Book value per share (Unadj.) Rs320.4130.5 245.6%  
Shares outstanding (eoy) m89.352,406.60 3.7%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.28.1 39.4%   
Avg P/E ratio x48.348.7 99.3%  
P/CF ratio (eoy) x27.640.1 68.8%  
Price / Book Value ratio x3.57.3 48.3%  
Dividend payout %21.45.1 419.0%   
Avg Mkt Cap Rs m100,9882,294,813 4.4%   
No. of employees `0004.714.7 31.8%   
Total wages/salary Rs m4,98847,971 10.4%   
Avg. sales/employee Rs Th6,730.019,169.8 35.1%   
Avg. wages/employee Rs Th1,063.63,253.0 32.7%   
Avg. net profit/employee Rs Th445.53,197.9 13.9%   
INCOME DATA
Net Sales Rs m31,564282,697 11.2%  
Other income Rs m1,2126,170 19.6%   
Total revenues Rs m32,776288,867 11.3%   
Gross profit Rs m5,21383,239 6.3%  
Depreciation Rs m1,57310,135 15.5%   
Interest Rs m1,8034,769 37.8%   
Profit before tax Rs m3,04974,505 4.1%   
Minority Interest Rs m127-11,126 -1.1%   
Prior Period Items Rs m-27-19 143.9%   
Extraordinary Inc (Exp) Rs m-371-6,852 5.4%   
Tax Rs m6899,349 7.4%   
Profit after tax Rs m2,08947,159 4.4%  
Gross profit margin %16.529.4 56.1%  
Effective tax rate %22.612.5 180.0%   
Net profit margin %6.616.7 39.7%  
BALANCE SHEET DATA
Current assets Rs m35,949308,646 11.6%   
Current liabilities Rs m19,402132,477 14.6%   
Net working cap to sales %52.462.3 84.1%  
Current ratio x1.92.3 79.5%  
Inventory Days Days7183 85.5%  
Debtors Days Days12788 144.5%  
Net fixed assets Rs m34,478133,606 25.8%   
Share capital Rs m8942,407 37.1%   
"Free" reserves Rs m22,601266,909 8.5%   
Net worth Rs m28,632314,042 9.1%   
Long term debt Rs m27,45531,167 88.1%   
Total assets Rs m76,591542,196 14.1%  
Interest coverage x2.716.6 16.2%   
Debt to equity ratio x1.00.1 966.2%  
Sales to assets ratio x0.40.5 79.0%   
Return on assets %5.19.6 53.1%  
Return on equity %7.315.0 48.6%  
Return on capital %8.217.8 46.0%  
Exports to sales %48.114.0 343.9%   
Imports to sales %14.53.1 460.3%   
Exports (fob) Rs m15,19239,572 38.4%   
Imports (cif) Rs m4,5658,882 51.4%   
Fx inflow Rs m16,61242,171 39.4%   
Fx outflow Rs m5,29221,583 24.5%   
Net fx Rs m11,32020,588 55.0%   
CASH FLOW
From Operations Rs m71767,694 1.1%  
From Investments Rs m-22,284-44,549 50.0%  
From Financial Activity Rs m29,488-19,243 -153.2%  
Net Cashflow Rs m8,0733,902 206.9%  

Share Holding

Indian Promoters % 27.7 63.7 43.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 37.8 5.1 736.8%  
FIIs % 8.6 23.0 37.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 8.3 312.0%  
Shareholders   56,241 133,026 42.3%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES SHASUN LTD With:   ASTRAZENECA PHARMA  ALEMBIC PHARMA  CADILA HEALTHCARE  GSK PHARMA  PANACEA BIOTECH  

Compare STRIDES SHASUN LTD With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Flat Note; Dr Reddy's & Lupin Surge over 2%(Closing)

Indian share markets continued to trade just above the dotted line in the afternoon session in a lackluster day of trading. At the closing bell, the BSE Sensex closed higher by 33 points.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Sun Pharma: USFDA Observations Post Good Quarterly Performance (Quarterly Results Update - Detailed)

Dec 12, 2016

Sun Pharma has announced its September quarter (2QFY17) results. The company has reported 13.2% YoY growth in sales and a growth of 117% in the net profits. Here is our analysis of the results.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES SHASUN LTD SHARE PRICE


Aug 22, 2017 (Close)

TRACK STRIDES SHASUN LTD

  • Track your investment in STRIDES SHASUN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES SHASUN LTD

STRIDES SHASUN LTD 8-QTR ANALYSIS

COMPARE STRIDES SHASUN LTD WITH

MARKET STATS